Alzheimer's Disease
44 videos · last 6 months shuffled daily, then older videos newest first
▶
51:44 What Should Mild Cognitive Impairment Trials Measure?
University of Bristol senior research associate Victoria presents a core outcome set for mild cognitive impairment trials, developed with people with MCI, family members, researchers and healthcare professionals, in a Dementia Researcher session.
▶
1:04:15 ADRF2026: Remternetug, Donanemab and p-tau217
Australian Dementia Network symposium talks from ADRF2026 cover screening and baseline data in the Phase 3 TRAILRUNNER-ALZ 3 trial of remternetug, further TRAILBLAZER-ALZ 2 donanemab insights and plasma p-tau217 models from A4/LEARN.
▶
4:39:39 Down Syndrome-Associated Alzheimer's Disease: EL-PFDD Meeting
The National Down Syndrome Society's Externally-Led Patient-Focused Drug Development meeting let the FDA hear from patients, families and caregivers about the symptoms and daily impact of Down syndrome-associated Alzheimer's disease.
▶
41:58 Inside the Alzheimer’s Drug Pipeline: What New Clinical Trials Mean for the Future
Dr. Jeffrey Cummings of the University of Nevada Las Vegas on the Alzheimer's treatment pipeline, where 182 trials evaluated 138 novel drugs in 2025 alone.
▶
43:19 Neuroimaging and Blood Biomarkers in Alzheimer's Trials
Bob Dagher, MD, Chief Medical Officer at Clinilabs, and Robin Wolz, PhD, Chief Scientific and Medical Officer at IXICO, discuss neuroimaging, blood-based biomarkers and multimodal approaches for patient selection and efficacy assessment in Alzheimer's trials.
▶
2:19 The Impact of Plasma P-Tau217: Pre-Screening and Selecting Participants for AD Trials
Pamela Lukasewicz Ferreira of the University of Pittsburgh on using plasma p-tau217 to pre-screen and select participants for Alzheimer's trials, reducing the need for costly PET scans.
▶
1:21:05 Clinical Trials for Down Syndrome-Associated Alzheimer’s Disease
Beau Ances, MD, a neurologist and researcher at Washington University in St. Louis, describes current clinical trials in Down syndrome-associated Alzheimer's disease, what taking part involves and why families do, for the National Down Syndrome Society.
▶
1:52 Initial Clinical Evaluation of [18]aci-19626, a First-In-Class TDP-43 PET Tracer
Alexis Moscoso of the University of Gothenburg, interviewed at AAIC 2026, on the initial clinical evaluation of [18]aci-19626, a PET tracer designed to visualise TDP-43 aggregates in Alzheimer's disease.
▶
28:01 Alzheimer's Research Updates from AAIC 2026
Dr. Crystal Glover and Dr. Joshua Grill of UCI discuss advances in Alzheimer's and dementia research and updates on clinical trials from the Alzheimer's Association International Conference 2026 in London, for UCI MIND.
▶
23:05 Moonshots & Milestones: The Future of Neurodegeneration Drug Discovery, AD/PD™ Session Spotlight
A fireside debate from the AD/PD 2026 International Conference on whether the future of neurodegeneration drug discovery lies with startups, big pharma or academia.
▶
2:24 Joining a Lecanemab Trial Before Alzheimer's Symptoms
The Post and Courier follows Jock Stender, who watched his late mother live with Alzheimer's disease and joined a Charleston clinical trial testing whether lecanemab can help people before they show cognitive decline.
▶
5:01 Why "Earlier Diagnosis" Changes What a CNS Trial Needs to Look Like
Francesco Bibbiani and Marty Kraut of Avance Clinical's CNS Center of Excellence discuss how diagnosing Alzheimer's disease before symptoms appear changes trial eligibility, endpoints and design.
▶
47:03 Clinically Meaningful Differences in Progressive Disease Trials
Berry Consultants' Dr. Scott Berry argues on the In the Interim podcast that responder analyses and time saved suit progressive-disease trials better than mean differences, citing pancreatic cancer, emphysema, Alzheimer's and IVF.
▶
38:08 Babylon Biosciences on AI and Alzheimer's Drug Development
Sacha Schermerhorn, Founder and CEO of Babylon Biosciences, discusses Alzheimer's drug development, biomarker-based trial design for small molecules and an AI model built with OpenAI to forecast clinical trial success, on Power to the Patients.
▶
39:57 AAIC 2026 Findings for Familial Alzheimer's Families
Youngtimers reviews findings from AAIC 2026 and the DIAD Family Conference for familial Alzheimer's families, including results for tau drugs E2814 and diranersen, blood tests and prevention trials starting earlier.
▶
28:32 Can Brain Tissue Be Regenerated? Inside the ReGenBrain Trial
Roberta Diaz Brinton, PhD, of the University of Arizona explains the Phase 2 ReGenBRAIN trial testing whether allopregnanolone can repair brain damage and improve thinking in people with mild Alzheimer's who carry APOE ε4, and who can enroll.
▶
43:01 Alzheimer’s and Gum Disease: Exploring the Role of Oral Bacteria in Brain Health
Dr. Michael J. Detke of Lighthouse Pharma discusses the SPRING clinical trial and the investigational oral drug LHP588, which is being studied as a potential way to reduce bacteria-related brain damage.
▶
2:58 Clinical Trials Using Peloton Bikes to CYCLE Against Alzheimer's Disease
The CYCLE-AD (Cycling to Cease or Limit the Effects of Alzheimer's Disease) clinical trial at Cleveland Clinical looks at whether high intensity exercise can delay or prohibit Alzheimer's disease in the 20-30% of the US Population that carry a gene (Apolipoprotein E4) that may put them at higher risk of developing Alzheimer's disease.
▶
5:58 FDA Broke Own Protocols in Approval of Biogen's Aduhelm for Alzheimer's
Video looks at how Biogen came up with the price tag for Aduhelm, which was based, at least in part, on surveying insurance companies.
▶
7:29 LIGHT4LIFE Study Will Look At Brain-Gut Photobiomodulation Using REGEnLIFE RGn600 as Possible Alzheimer’sTtreatment
Jacques Touchon, MD, PhD, University Hospital of Montpellier, Montpellier, France discusses Brain-Gut Photobiomodulation using REGEnLIFE RGn600 as a possible part of Alzheimer’s treatment and a different approach to targeting amyloid-β 42 or tau such as inflammation.
▶
1:00:21 Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
A Fierce Biotech webinar on what has been learned about Alzheimer's disease over the last five years, and neuroinflammation as the next step in research and development.
▶
59:09 Annovis Patients' Live Forum: Your Questions Answered (February 27, 2025)
Annovis Bio CEO Maria Maccecchini updates patients on the Phase 3 Alzheimer's trial and plans for Phase 3 Parkinson's and open-label extension studies, and takes audience questions.
▶
4:26 A Look at the ADCOMS Score Alzheimer’s Disease Clinical Trials Endpoint
Weill Cornell Medicine and New York-Presbyterian physician Dr. Richard Isaacson discusses endpoints in Alzheimer’s disease clinical trials,. including the Alzheimer's Disease Composite Score endpoint, also called the ADCOMS endpoint.
▶
5:57 Video on FDA Fast Track Approval of Biogen Eisai's Alzheimer's Drug Featuring CEO
The new Alzheimer's Drug from Biogen-Eisai Lecanemab received "Accelerated approval" following clinical trials and will file for "Full approval" and costs $26,500 a year; which is not yet covered by Medicare.